Search

Baseball Legend Bernie Williams Calls on the Public to Join Queen Latifah, The Bacon Brothers, Paul Shaffer, as Judges of the Breathless® Ballad Challenge

Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

FDA accepts Jardiance sNDA for T2D in children 10 and older

The US FDA has accepted a supplemental New Drug Application for Jardiance® (empagliflozin) tablets as a potential treatment for children 10 years and older with type 2 diabetes

Shelter Bowl: These pets looking for a new home were the big winners

Dogs and cats in a pair of shelters were met with generous donations – and some footballs - thanks to a program committed to improving their future and well-being.

Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

Fur-ever homes: How pet shelters and fosters have met the challenge of the pandemic

Pet shelters impacted by the COVID-19 pandemic have benefitted from the Stay Home and Foster program, which connects shelter pets with foster homes.

US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch

Championing minds for generations both in and out of the workplace

Boehringer Ingelheim is now certified for Mental Health America’s (MHA) Bell Seal for Workplace Mental Health.

Championing Novel Science

2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

Global Careers Page | Boehringer Ingelheim

Join a global team of more than 52,000 passionate and talented individuals dedicated to improving the health of humans and animals worldwide.

SEMINTRA® (Telmisartan Oral Solution) | Boehringer Ingelheim US

Introducing SEMINTRA® (telmisartan oral solution) —The first FDA-approved liquid solution for the control of systemic feline hypertension.

The power of patient advocacy in cancer care

Patients and advocacy organizations agree that patient empowerment is key to quality cancer care

Transboundary and Emerging Diseases | Boehringer Ingelheim US

Click here to find out more on how Boehringer Ingelheim fights transboundary and emerging diseases through cutting-edge technologies.

Our Mission

Our Story

U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)

How Boehringer Ingelheim US Helps Injured Veterans | Boehringer Ingelheim US

Read more on how Boehringer Ingelheim supports injured veterans in making a fresh start through the use of service dogs, with the Warrior Canine Connection.

The Importance of Drug Discovery | R&D | Boehringer Ingelheim US

Research & Development

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D

FDA Grants BTD for Investigational Treatment of CIAS | BI US

Learn about the breakthrough therapy designation grant for BI's latest investigational treatment of cognitive impairment associated with schizophrenia.

The View from Both Sides of the Table

Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers